TransCode Therapeutics Inc.
RNAZ | NASDAQ
$1.79
+$0.03 (+1.70%)
Sep 22, 2026, 11:42 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.13 | -1.40 | -1.23 | -4.76 | -2.03K | -9.32K |
PEG Ratio | -0.01 | 0.01 | 0.01 | 0 | -16.82 | -30.25 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 0.46 | -11.66 | 14.10 | 1.74K | 678.39 | -6.41K |
P/FCF Ratio | -0.24 | -1.76 | -1.28 | -356.09 | -2.51K | -44.3K |
P/OCF Ratio | -0.24 | -1.76 | -1.28 | -358.37 | -2.63K | -44.3K |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | n/a | -0.02 | 0.27 | n/a | n/a | -0.61 |
Quick Ratio | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 | 2.05 |
Current Ratio | 6.29 | 2.56 | 1.28 | 1.70 | 8.97 | 2.05 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | -4.23K | -584.07 | -347.39 | -1.06 | -64.70 | -1.84 |
Return on Equity | -335.36% | 829.97% | -1.13K% | -542.01% | -33.54% | 68.77% |
Return on Assets | -21.34% | -229.69% | -358.75% | -231.48% | -29.83% | -222.09% |
Return on Invested Capital | -17.61% | -343.36% | -928.50% | -575.98% | -30.15% | -111.70% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove RNAZ